Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 497 across all filing types
Latest filing 2026-05-19 Capital/Financing Update
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Hansa Biopharma ingår licensavtal värt 115 miljoner euro med SERB Pharmaceuticals för IDEFIRIX i Europa och MENA
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a licensing agreement between Hansa Biopharma and SERB Pharmaceuticals for the commercialization of a drug (IDEFIRIX) in Europe and MENA regions. It includes details about the financial terms of the deal, strategic implications, and background information about the drug and companies involved. It also mentions a conference call for investors. The document does not contain financial statements, detailed financial performance data, or comprehensive management discussion and analysis. It is primarily an announcement of a capital/financing transaction and strategic partnership. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the financing and licensing deal, supporting a high confidence classification.
2026-05-19 English
Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a €115 million licensing agreement between Hansa Biopharma and SERB Pharmaceuticals for the commercialization of IDEFIRIX in Europe and MENA. It includes details about the agreement, financial terms, strategic implications, and a conference call announcement. The document does not contain financial statements, detailed financial performance data, or comprehensive management discussion and analysis. It is primarily a corporate announcement about a licensing deal and related financial terms, not a report or transcript. The presence of a conference call announcement suggests it is related to investor communication but is not itself a call transcript or investor presentation. Given these characteristics, the document best fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length (over 12,000 characters) and detailed content support this classification rather than a brief announcement or regulatory filing.
2026-05-19 English
Notice to Annual General Meeting in Hansa Biopharma AB (publ)
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a detailed notice to shareholders of the upcoming Annual General Meeting, including participation instructions, agenda items, proposals, proxy and advance voting procedures. This is exactly proxy solicitation / information statement material sent to shareholders ahead of an AGM. Therefore it should be classified as PSI.
2026-04-28 English
Kallelse till årsstämma i Hansa Biopharma AB (publ)
Proxy Solicitation & Information Statement Classification · 87% confidence The document is a formal notice (“kallelse”) convening an Annual General Meeting, including agenda items, participation instructions, voting procedures, and detailed proposals to shareholders. It is sent to shareholders to provide information and solicit votes, matching the definition of a Proxy Solicitation & Information Statement.
2026-04-28 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport' which translates to 'Interim Report' and covers the period January to March 2026 (Q1 2026). It contains detailed financial data including revenue, operating costs, net results, cash flow, and other financial metrics for Q1 2026 compared to Q1 2025 and the full year 2025. It also includes operational updates, clinical project portfolio updates, regulatory milestones, and outlook commentary. The length is substantial (15,000 characters) and the content includes actual financial statements and substantive analysis, not just an announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2026-04-23 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'Interim Report' and covers the period 'January - March 2026'. It contains comprehensive financial statements, including a 'Financial Summary' table with comparative data for Q1 2026 and Q1 2025, as well as detailed management commentary on business operations, clinical pipeline updates, and financial performance. It meets the criteria for an Interim/Quarterly Report as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q1 2026
2026-04-23 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.